Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio
Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio
NEW YORK, Sept. 19, 2022 /PRNewswire/ -- The male hypogonadism market has been segmented by type (Klinefelter syndrome, Kallmann syndrome, and pituitary disorders) and geography (North America, Europe, Asia, and Rest of World (ROW)). North America will account for 37% of the market's growth during the forecast period. This growth is attributed to factors such as the significant increase in the prevalence of male hypogonadism. Moreover, market growth in this region will be faster than the growth of the market in other regions. The US and Canada are the key countries for the male hypogonadism market in North America.
紐約，9月2022年19號/美通社/--男性性腺功能減退症市場已按類型(Klinefelter綜合徵、Kallmann綜合徵和垂體疾病)和地理位置(北美、歐洲、亞洲和世界其他地區(排))。北美將在預測期內佔市場增長的37%。這一增長歸因於男性性腺功能低下症患病率顯著增加等因素。此外，該地區的市場增長將快於其他地區的市場增長。美國和加拿大是#年男性性腺功能減退市場的主要國家。北美.
The male hypogonadism market size is estimated to grow by USD 684.95 mn from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 5.09% during the forecast period.
據估計，從2021年到2026年，男性性腺功能減退的市場規模將增長684.95美元。此外，在預測期內，市場的增長勢頭將以5.09%的複合年均增長率加速。
Technavio provides a comprehensive report summary describing the market size and forecast along with research methodology. The FREE sample report is available in PDF format
Technavio提供了一份全面的報告摘要，描述了市場規模和預測以及研究方法。免費樣本報告以PDF格式提供
The male hypogonadism market report includes information on the product launches, sustainability, and prospects of leading vendors, including AbbVie Inc., Aytu BioPharma Inc., Bayer AG, Bio Techne Corp., Diurnal Group Plc, Eli Lilly and Co., Endo International Plc, Ferring B.V., IBSA Institute Biochimique SA, Lipocine Inc., Merck and Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. The key offerings of some of these vendors are listed below:
男性性腺功能減退市場報告包括領先供應商的產品推出、可持續性和前景的信息，這些供應商包括艾伯維公司公司、愛圖生物製藥公司、拜耳公司、Bio Techne公司、Diurial Group Plc、禮來、Endo International Plc、Ferring B.V.、IBSA Institute BioChimique SA、利普辛公司、默克公司、Perrigo Co.PLC、輝瑞和Teva製藥工業有限公司。其中一些供應商的主要產品如下：
- AbbVie Inc. - The company offers male hypogonadism treatment, through its Testosterone Gel.
- Bayer AG - The company offers Hormone-replacement therapies, which can help men with testosterone deficiency and improve their mental and physical well-being, sexual satisfaction, and quality of life.
- Eli Lilly and Co. - The company offers treatment of testosterone deficiency (hypogonadism) in men, through its AXIRON testosterone solution.
- Endo International Plc - The company offers treatment of testosterone deficiency (hypogonadism) in men through testosterone replacement therapy.
- Ferring B.V. - The company offers Testavan treatment options for men with hypogonadism, which is designed to enhance bioavailability. It is administered with a convenient hands-free applicator.
- IBSA Institute Biochimique SA - The company offers treatment of testosterone deficiency through its subsidiary, IBSA Pharma SAS.
- 艾伯維公司。-該公司通過其睾丸素凝膠提供男性性腺功能減退的治療。
- 拜耳股份公司該公司提供激素替代療法，可以幫助患有睾丸素缺乏的男性，改善他們的身心健康、性滿意度和生活質量。
- 禮來。-該公司通過其AxIron睾丸素解決方案提供男性睾丸素缺乏(性腺功能減退)的治療。
- 遠藤國際公司-該公司通過睾酮替代療法治療男性睾丸素缺乏(性腺功能減退)。
- 費林B.V.-該公司為性腺功能減退的男性提供Testavan治療選項，旨在提高生物利用度。它是通過一個方便的免提塗布器進行管理的。
- IBSA研究所生物嵌合體SA-該公司通過其子公司IBSA Pharma SAS提供治療睾丸素缺乏的藥物。
Technavio's reports provide key strategic initiatives used by vendors, along with key news and the latest developments. View our FREE PDF Sample Report Now
Technavio的報告提供了供應商使用的關鍵戰略舉措，以及關鍵新聞和最新發展。立即查看我們的免費PDF示例報告
The competitive scenario provided in the male hypogonadism market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.
男性性腺功能減退症市場報告中提供的競爭情景基於各種業績指標對公司進行分析、評估和定位。本分析考慮的一些因素包括公司過去幾年的財務業績、增長戰略、產品創新、新產品的推出、投資、市場份額的增長等。
Factors such as an increase in the incidence of hypogonadism and the increasing awareness about male hypogonadism and its treatment options will be crucial in driving the growth of the market. However, the loss of patent exclusivities and increasing generic competition will restrict the market growth.
性腺功能減退症發病率增加以及人們對男性性腺功能減退症及其治療選擇的認識日益提高等因素，將是推動市場增長的關鍵因素。然而，專利排他性的喪失和日益加劇的仿製藥競爭將制約市場增長。
Technavio has identified key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report
Technavio已經確定了市場中的主要趨勢、驅動因素和挑戰，這將幫助供應商改進他們的戰略，以保持領先於競爭對手。查看我們的免費PDF示例報告
Sexually Transmitted Diseases (STD) Treatment Market by Service and Geography - Forecast and Analysis 2022-2026: The sexually transmitted diseases (STD) treatment market share is expected to increase by USD 13.48 billion from 2021 to 2026.
按服務和地域劃分的性傳播疾病(STD)治療市場-2022-2026年預測與分析：從2021年到2026年，性傳播疾病(STD)治療市場份額預計將增加134.8億美元。
Sexual Enhancement Supplements Market by Product and Geography - Forecast and Analysis 2022-2026: The sexual enhancement supplements market share is expected to increase by USD 801.29 million from 2021 to 2026.
按產品和地域劃分的性增強補充劑市場-2022-2026年預測與分析：2021年至2026年，性增強補充劑的市場份額預計將增加8.0129億美元。
|
Male Hypogonadism Market Scope | |
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.09% |
|
Market growth 2022-2026 |
USD 684.95 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
3.52 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 37% |
|
Key consumer countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
|
Companies profiled |
AbbVie Inc., Aytu BioPharma Inc., Bayer AG, Bio Techne Corp., Diurnal Group Plc, Eli Lilly and Co., Endo International Plc, Ferring B.V., IBSA Institute Biochimique SA, Lipocine Inc., Merck and Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. |
|
Market Dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
|
男性性腺功能減退症的市場範圍 | |
|
報告覆蓋範圍 |
細節 |
|
頁碼 |
120 |
|
基準年 |
2021 |
|
預測期 |
2022-2026 |
|
增長動能和複合年增長率 |
以5.09%的複合年均增長率加速 |
|
2022-2026年市場增長 |
6.8495億美元 |
|
市場結構 |
支離破碎 |
|
同比增長(%) |
3.52 |
|
區域分析 |
北美、歐洲、亞洲和世界其他地區(行) |
|
業績市場貢獻 |
北美為37% |
|
主要消費國 |
美國、加拿大、德國、英國和中國 |
|
競爭格局 |
領先公司、競爭戰略、消費者參與範圍 |
|
公司簡介 |
艾伯維公司、Aytu BioPharma Inc.、拜耳股份公司、Bio Techne Corp.、DAURNAL Group Plc、禮來、Endo International Plc、Ferring B.V.、IBSA Institute BioChimique SA、利普辛公司、默克公司、Perrigo Co.PLC、輝瑞和Teva製藥工業有限公司。 |
|
市場動態 |
母市場分析，市場增長誘因和障礙，快增長和慢增長細分市場分析，新冠肺炎影響和未來消費者動態，以及預測期內的市場狀況分析。 |
|
自定義權限 |
如果我們的報告沒有包括您正在尋找的數據，您可以聯繫我們的分析師並定製細分市場。 |
Browse Health Care Market Reports
瀏覽醫療市場報告
1 Executive Summary
1執行摘要
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
- 1.1市場概述
- 圖01：執行摘要-市場概覽圖表
- 圖02：執行摘要-市場概覽數據表
- 圖03：執行摘要--全球市場特徵圖表
- 圖04：執行摘要-按地域劃分的市場圖表
- 圖05：執行摘要-按類型劃分的市場細分圖表
- 圖06：執行摘要-增量增長圖表
- 圖07：執行摘要-增量增長數據表
- 圖08：執行摘要-供應商市場定位圖表
2 Market Landscape
2市場格局
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
- 2.1市場生態系統
- 圖09：母市場
- 圖表10：市場特徵
3 Market Sizing
3市場規模調整
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.1市場定義
- 表11：市場定義中包括的供應商的產品
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.2細分市場分析
- 圖12：細分市場
- 3.3 Market size 2021
- 3.3 2021年市場規模
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
- 3.4市場展望：2021-2026年預測
- 圖表13：2021-2026年全球市場規模及預測圖表(百萬美元)
- 圖表14：2021-2026年全球市場規模及預測數據表(百萬美元)
- 圖表15：全球市場圖表：2021-2026年同比增長(%)
- 圖表16：全球市場數據表：2021-2026年同比增長(%)
4 Five Forces Analysis
四、五力分析
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between2021 and 2026
- 4.1五力總結
- 圖17：五力分析--2021年與2026年的對比
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.2買家的議價能力
- 圖表18：買家議價能力圖表--2021年和2026年關鍵因素的影響
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.3供應商的議價能力
- 圖表19：供應商議價能力--2021年和2026年關鍵因素的影響
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.4新進入者的威脅
- 圖20：新進入者的威脅--2021年和2026年關鍵因素的影響
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.5替補球員的威脅
- 圖21：替代品的威脅--2021年和2026年關鍵因素的影響
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.6競爭威脅
- 圖22：競爭的威脅--2021年和2026年關鍵因素的影響
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
- 4.7市況
- 圖表23：2021年和2026年五股力量行情圖表
5 Market Segmentation by Type
5按類型劃分的市場細分
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.1細分市場
- 圖表24：2021-2026年類型-市場份額圖表(%)
- 圖25：2021-2026年類型-市場份額數據表(%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.2按類型比較
- 圖26：按類型進行比較的圖表
- 圖27：按類型比較的數據表
- 5.3 Klinefelters syndrome - Market size and forecast 2021-2026
- Exhibit 28: Chart on Klinefelters syndrome - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Klinefelters syndrome - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Klinefelters syndrome - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Klinefelters syndrome - Year-over-year growth 2021-2026 (%)
- 5.3 Klinefelters綜合徵--市場規模和2021-2026年預測
- 圖表28：Klinefelters綜合徵圖表--市場規模和2021-2026年預測(百萬美元)
- 圖表29：Klinefelters綜合徵數據表--市場規模和2021-2026年預測(百萬美元)
- 圖表30：Klinefelters綜合徵圖表-2021-2026年同比增長(%)
- 圖表31：Klinefelters綜合徵數據表--2021-2026年間的年增長率(%)
- 5.4 Kallmann syndrome - Market size and forecast 2021-2026
- Exhibit 32: Chart on Kallmann syndrome - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Kallmann syndrome - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Kallmann syndrome - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Kallmann syndrome - Year-over-year growth 2021-2026 (%)
- 5.4卡爾曼綜合徵--市場規模和2021-2026年預測
- 圖表32：卡爾曼綜合症圖表--市場規模和2021-2026年預測(百萬美元)
- 圖表33：Kallmann綜合徵數據表--市場規模和2021-2026年預測(百萬美元)
- 圖表34：Kallmann綜合徵圖表--2021-2026年同比增長(%)
- 圖表35：Kallmann綜合徵數據表--2021-2026年間的年增長率(%)
- 5.5 Pituitary disorders - Market size and forecast 2021-2026
- Exhibit 36: Chart on Pituitary disorders - Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Pituitary disorders - Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Pituitary disorders - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Pituitary disorders - Year-over-year growth 2021-2026 (%)
- 5.5垂體性疾病--市場規模和2021-2026年預測
- 圖表36：垂體性疾病圖表--2021-2026年市場規模和預測(百萬美元)
- 圖表37：垂體性疾病數據表--2021-2026年市場規模和預測(百萬美元)
- 圖表38：垂體性疾病圖表--2021-2026年間的年增長率(%)
- 圖表39：垂體性疾病數據表--2021-2026年的年增長率(%)
- 5.6 Market opportunity by Type
- Exhibit 40: Market opportunity by Type ($ million)
- 5.6按類型劃分的市場機會
- 圖表40：按類型劃分的市場機會(百萬美元)
6 Customer Landscape
6客户環境
- 6.1 Customer landscape overview
- Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 6.1客户環境概述
- 圖41：價格敏感度、生命週期、客户購物籃、採用率和購買標準分析
7 Geographic Landscape
7地理景觀
- 7.1 Geographic segmentation
- Exhibit 42: Chart on Market share by geography 2021-2026 (%)
- Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
- 7.1地理分段
- 圖表42：2021-2026年按地域劃分的市場份額圖表(%)
- 圖43：2021-2026年按地域劃分的市場份額數據表(%)
- 7.2 Geographic comparison
- Exhibit 44: Chart on Geographic comparison
- Exhibit 45: Data Table on Geographic comparison
- 7.2地理位置比較
- 圖44：地理對比圖表
- 圖45：地理對比數據表
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.3 北美-市場規模和2021-2026年預測
- 圖46：圖表北美-市場規模和2021-2026年預測(百萬美元)
- 圖47：數據表北美-市場規模和2021-2026年預測(百萬美元)
- 圖表48：圖表北美-2021-2026年同比增長(%)
- 圖49：數據表北美-2021-2026年同比增長(%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.4 歐洲-市場規模和2021-2026年預測
- 圖表50：圖表歐洲-市場規模和2021-2026年預測(百萬美元)
- 圖51：數據表歐洲-市場規模和2021-2026年預測(百萬美元)
- 圖52：圖表歐洲-2021-2026年同比增長(%)
- 圖53：數據表歐洲-2021-2026年同比增長(%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.5 亞洲-市場規模和2021-2026年預測
- 圖54：圖表亞洲-市場規模和2021-2026年預測(百萬美元)
- 圖55：數據表亞洲-市場規模和2021-2026年預測(百萬美元)
- 圖56：圖表亞洲-2021-2026年同比增長(%)
- 圖57：數據表亞洲-2021-2026年同比增長(%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.6世界其他地區(ROW)--市場規模和2021-2026年預測
- 圖表58：世界其他地區圖表(行)-2021-2026年市場規模和預測(百萬美元)
- 圖表59：世界其他地區數據表(行)--2021-2026年市場規模和預測(百萬美元)
- 圖表60：2021-2026年世界其他地區同比增長圖表(行)(%)
- 圖表61：世界其他地區(ROW)-2021-2026年同比增長數據表(%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.7美國-2021-2026年市場規模和預測
- 圖表62：美國市場規模和2021-2026年預測圖表(百萬美元)
- 圖表63：美國2021-2026年市場規模及預測數據表(百萬美元)
- 圖表64：美國2021-2026年同比增長圖表(%)
- 圖表65：美國2021-2026年同比增長數據表(%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.8 德國-市場規模和2021-2026年預測
- 圖表66：圖表德國-市場規模和2021-2026年預測(百萬美元)
- 圖67：數據表德國-市場規模和2021-2026年預測(百萬美元)
- 圖表68：圖表德國-2021-2026年同比增長(%)
- 圖69：數據表德國-2021-2026年同比增長(%)
- 7.9 China - Market size and forecast 2021-2026
- Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.9 中國-市場規模和2021-2026年預測
- 圖表70：圖表中國-市場規模和2021-2026年預測(百萬美元)
- 圖71：數據表中國-市場規模和2021-2026年預測(百萬美元)
- 圖72：圖表中國-2021-2026年同比增長(%)
- 圖73：數據表中國-2021-2026年同比增長(%)
- 7.10 UK - Market size and forecast 2021-2026
- Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10英國-市場規模和預測2021-2026
- 圖表74：英國市場規模和2021-2026年預測圖表(百萬美元)
- 圖表75：英國市場規模數據表及2021-2026年預測(百萬美元)
- 圖表76：英國2021-2026年同比增長圖表(%)
- 圖表77：英國2021-2026年同比增長數據表(%)
- 7.11 Canada - Market size and forecast 2021-2026
- Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 加拿大-市場規模和2021-2026年預測
- 圖表78：圖表加拿大-市場規模和2021-2026年預測(百萬美元)
- 圖79：數據表加拿大-市場規模和2021-2026年預測(百萬美元)
- 圖表80：圖表加拿大-2021-2026年同比增長(%)
- 圖81：數據表加拿大-2021-2026年同比增長(%)
- 7.12 Market opportunity by geography
- Exhibit 82: Market opportunity by geography ($ million)
- 7.12按地理位置劃分的市場機會
- 圖表82：按地理位置劃分的市場機會(百萬美元)
8 Drivers, Challenges, and Trends
8個驅動因素、挑戰和趨勢
- 8.1 Market drivers
- 8.1市場驅動因素
- 8.2 Market challenges
- 8.2市場挑戰
- 8.3 Impact of drivers and challenges
- Exhibit 83: Impact of drivers and challenges in 2021 and 2026
- 8.3驅動因素和挑戰的影響
- 圖83：2021年和2026年驅動因素和挑戰的影響
- 8.4 Market trends
- 8.4市場趨勢
9 Vendor Landscape
9供應商情況
- 9.1 Overview
- 9.1概述
- 9.2 Vendor landscape
- Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
- 9.2供應商景觀
- 圖84：關於投入的關鍵程度和區分因素的概覽
- 9.3 Landscape disruption
- Exhibit 85: Overview on factors of disruption
- 9.3景觀破壞
- 圖85：中斷因素概覽
- 9.4 Industry risks
- Exhibit 86: Impact of key risks on business
- 9.4行業風險
- 圖表86：關鍵風險對業務的影響
10 Vendor Analysis
10供應商分析
- 10.1 Vendors covered
- Exhibit 87: Vendors covered
- 10.1涵蓋的供應商
- 圖表87：涵蓋的供應商
- 10.2 Market positioning of vendors
- Exhibit 88: Matrix on vendor position and classification
- 10.2供應商的市場定位
- 圖表88：關於供應商地位和分類的矩陣
- 10.3 AbbVie Inc.
- Exhibit 89: AbbVie Inc. - Overview
- Exhibit 90: AbbVie Inc. - Product / Service
- Exhibit 91: AbbVie Inc. - Key offerings
- 10.3艾伯維公司。
- 證據89：艾伯維公司。-概覽
- 證據90：艾伯維公司--產品/服務
- 證物91：艾伯維公司--主要產品
- 10.4 Bayer AG
- Exhibit 92: Bayer AG - Overview
- Exhibit 93: Bayer AG - Business segments
- Exhibit 94: Bayer AG - Key offerings
- Exhibit 95: Bayer AG - Segment focus
- 10.4拜耳股份公司
- 圖92：拜耳股份公司-概覽
- 圖93：拜耳股份公司--業務細分
- 圖94：拜耳股份公司-主要產品
- 圖95：拜耳股份公司-細分市場焦點
- 10.5 Eli Lilly and Co.
- Exhibit 96: Eli Lilly and Co. - Overview
- Exhibit 97: Eli Lilly and Co. - Product / Service
- Exhibit 98: Eli Lilly and Co. - Key offerings
- 10.5禮來。
- 證據96：禮來。-概覽
- 證據97：禮來--產品/服務
- 證物98：禮來--主要產品
- 10.6 Endo International Plc
- Exhibit 99: Endo International Plc - Overview
- Exhibit 100: Endo International Plc - Business segments
- Exhibit 101: Endo International Plc - Key news
- Exhibit 102: Endo International Plc - Key offerings
- Exhibit 103: Endo International Plc - Segment focus
- 10.6遠藤國際公司
- 展覽99：Endo International Plc-概覽
- 圖100：Endo International Plc-Business細分市場
- 展品101：遠藤國際公司-關鍵新聞
- 展覽102：Endo International Plc-Key Products
- 圖103：Endo International Plc-細分市場焦點
- 10.7 Ferring B.V.
- Exhibit 104: Ferring B.V. - Overview
- Exhibit 105: Ferring B.V. - Product / Service
- Exhibit 106: Ferring B.V. - Key offerings
- 10.7費林B.V.
- 展品104：Ferring B.V.-概覽
- 圖105：Ferring B.V.-產品/服務
- 展品106：Ferring B.V.-主要產品
- 10.8 IBSA Institute Biochimique SA
- Exhibit 107: IBSA Institute Biochimique SA - Overview
- Exhibit 108: IBSA Institute Biochimique SA - Product / Service
- Exhibit 109: IBSA Institute Biochimique SA - Key offerings
- 10.8 IBSA研究所生物嵌合體SA
- 展覽107：IBSA研究所生物嵌合體SA-概覽
- 圖108：IBSA研究所生物嵌合體SA-產品/服務
- 圖109：IBSA研究所生物嵌合體SA-主要產品
- 10.9 Lipocine Inc.
- Exhibit 110: Lipocine Inc. - Overview
- Exhibit 111: Lipocine Inc. - Product / Service
- Exhibit 112: Lipocine Inc. - Key offerings
- 10.9利普林公司。
- 展覽110：利普西因公司-概覽
- 展品111：利培林公司--產品/服務
- 展品112：利普西林公司-主要產品
- 10.10 Merck and Co. Inc.
- Exhibit 113: Merck and Co. Inc. - Overview
- Exhibit 114: Merck and Co. Inc. - Business segments
- Exhibit 115: Merck and Co. Inc. - Key news
- Exhibit 116: Merck and Co. Inc. - Key offerings
- Exhibit 117: Merck and Co. Inc. - Segment focus
- 10.10默克公司
- 圖表113：默克公司-概覽
- 圖114：默克公司-業務部門
- 證據115：默克公司-關鍵新聞
- 圖116：默克公司-主要產品
- 圖117：默克公司-細分市場焦點
- 10.11 Pfizer Inc.
- Exhibit 118: Pfizer Inc. - Overview
- Exhibit 119: Pfizer Inc. - Product / Service
- Exhibit 120: Pfizer Inc. - Key news
- Exhibit 121: Pfizer Inc. - Key offerings
- 10.11輝瑞。
- 證據：輝瑞。-概覽
- 圖119：輝瑞--產品/服務
- 證物120：輝瑞--關鍵新聞
- 圖121：輝瑞--主要產品
- 10.12 Teva Pharmaceutical Industries Ltd.
- Exhibit 122: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 123: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 124: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 125: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 126: Teva Pharmaceutical Industries Ltd. - Segment focus
- 10.12 Teva製藥工業有限公司
- 圖122：Teva製藥工業有限公司-概覽
- 圖123：Teva製藥工業有限公司--業務部門
- 展覽124：Teva製藥工業有限公司-主要新聞
- 圖125：Teva製藥工業有限公司-主要產品
- 圖126：Teva製藥工業有限公司--細分市場焦點
11 Appendix
11附錄
- 11.1 Scope of the report
- 11.1報告的範圍
- 11.2 Inclusions and exclusions checklist
- Exhibit 127: Inclusions checklist
- Exhibit 128: Exclusions checklist
- 11.2包括和排除清單
- 圖127：包含物清單
- 圖128：排除清單
- 11.3 Currency conversion rates for US$
- Exhibit 129: Currency conversion rates for US$
- 11.3美元的貨幣兑換率
- 圖表129：美元的貨幣兑換率
- 11.4 Research methodology
- Exhibit 130: Research methodology
- Exhibit 131: Validation techniques employed for market sizing
- Exhibit 132: Information sources
- 11.4研究方法
- 圖130：研究方法
- 圖131：用於市場規模確定的驗證技術
- 圖表132：信息來源
- 11.5 List of abbreviations
- Exhibit 133: List of abbreviations
- 11.5縮略語列表
- 圖表133：縮略語列表
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Technavio是一家全球領先的技術研究和諮詢公司。他們的研究和分析側重於新興市場趨勢，並提供可操作的見解，幫助企業識別市場機會並制定有效戰略，以優化其市場地位。Technavio的報告庫擁有500多名專業分析師，由17,000多份報告和報告組成，涵蓋50個國家和地區的800項技術。他們的客户羣包括各種規模的企業，其中包括100多家財富500強公司。不斷增長的客户基礎依賴於Technavio的全面覆蓋、廣泛的研究和可操作的市場洞察力，以確定現有和潛在市場中的機會，並評估它們在不斷變化的市場情景中的競爭地位。
Contact
聯繫方式
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website:
技術研究
傑西·邁達
媒體與營銷主管
美國：+1 844 364 1100
英國：+44 203 893 3200
電子郵件：[受電子郵件保護]
網站：
SOURCE Technavio
來源技術